Biodexa Pharmaceuticals Plc's Comment on Supply Chain
The company utilizes a contract manufacturer to produce clinical trial materials for its studies. It has entered into a license and collaboration agreement with Otsuka, granting an exclusive, worldwide (excluding Japan) license to develop, manufacture, and commercialize MTX240. The company is responsible for all development, manufacturing, and commercialization activities related to MTX240 within the licensed territory. Otsuka is identified as a supplier in company filings.
Biodexa Pharmaceuticals Plc's Comment on Supply Chain
The company utilizes a contract manufacturer to produce clinical trial materials for its studies. It has entered into a license and collaboration agreement with Otsuka, granting an exclusive, worldwide (excluding Japan) license to develop, manufacture, and commercialize MTX240. The company is responsible for all development, manufacturing, and commercialization activities related to MTX240 within the licensed territory. Otsuka is identified as a supplier in company filings.
Sources:
Biodexa Pharmaceuticals Plc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Biodexa Pharmaceuticals Plc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
